Home Ingredients 5-Loxin® (Boswellia AKBA — PLT/OmniActive)
Joint HealthAnti-Inflammatory

5-Loxin® (Boswellia AKBA — PLT/OmniActive)

Boswellia serrata
Evidence Level
Strong
3 Clinical Trials
3 Documented Benefits
4/5 Evidence Score

5-Loxin® is a branded Boswellia serrata gum resin extract standardized to a high level (at least 30%) of AKBA (3-O-acetyl-11-keto-beta-boswellic acid), the single most potent anti-inflammatory boswellic acid. AKBA blocks 5-lipoxygenase (5-LOX), an enzyme that drives the production of inflammatory leukotrienes in joints. Standardizing to AKBA is what separates 5-Loxin from ordinary boswellia, and it has been tested in several randomized controlled trials for knee osteoarthritis.

Studied Dose 100 to 250 mg once daily. Knee osteoarthritis trials used 100 mg/day and 250 mg/day over 90 days, with benefits seen as early as 7 days at the higher dose.
Active Compound Boswellia serrata gum resin extract standardized to at least 30% AKBA (3-O-acetyl-11-keto-beta-boswellic acid), the most potent 5-LOX-inhibiting boswellic acid.

Benefits

Knee osteoarthritis and joint comfort

In double-blind, placebo-controlled trials, 5-Loxin significantly reduced pain and improved physical function scores in people with knee osteoarthritis, with the 250 mg dose showing improvement within a week.

Supported by Trial 3, Trial 1

Joint mobility and stiffness

By calming the inflammatory cascade in the joint, the extract supports easier movement and reduced morning stiffness, complementing the pain benefits measured in clinical studies.

Supported by Trial 3

Cartilage-protective signaling

Trials reported reductions in matrix metalloproteinase-3 (MMP-3), an enzyme that breaks down cartilage, suggesting the extract supports the joint structure and not only symptoms.

Supported by Trial 1, Trial 3

Mechanism of action

1

5-LOX inhibition

AKBA selectively inhibits 5-lipoxygenase, lowering the production of pro-inflammatory leukotrienes that drive swelling and pain in arthritic joints.

2

Reduced cartilage-degrading enzymes

The extract lowers MMP-3 activity, an enzyme linked to the breakdown of joint cartilage, helping protect the joint matrix over time.

Clinical trials

1
5-Loxin for Knee Osteoarthritis — RCT
PubMed

Double-blind, randomized, placebo-controlled trial of 5-Loxin (100 mg and 250 mg/day) in patients with knee osteoarthritis over 90 days. (Sengupta et al. 2008, Arthritis Research & Therapy)

Adults with knee osteoarthritis.

Both doses significantly improved pain and function versus placebo, with the 250 mg dose producing benefits as early as 7 days and reducing the cartilage-degrading enzyme MMP-3.

2
5-Loxin vs Aflapin for Osteoarthritis — RCT
PubMed

Comparative randomized controlled study of 5-Loxin and Aflapin (a related boswellia extract) against placebo in knee osteoarthritis. (Sengupta et al. 2010, International Journal of Medical Sciences)

Adults with knee osteoarthritis.

Both boswellia extracts significantly improved pain and physical-function scores versus placebo over 90 days, confirming the AKBA-standardized approach.

3
Boswellia AKBA Extract for Knee OA — RCT
PubMed

Double-blind, randomized, placebo-controlled clinical study evaluating an AKBA-enriched boswellia extract in knee osteoarthritis. (Vishal et al. 2011, International Journal of Medical Sciences)

Adults with knee osteoarthritis.

The extract significantly reduced pain and stiffness and improved joint function versus placebo, supporting the consistency of the osteoarthritis findings.

Side effects and drug interactions

Common Potential side effects

GENERALLY WELL-TOLERATED — adverse events in trials were comparable to placebo.
Mild digestive upset, such as nausea or acid reflux, is occasionally reported.
Rarely, skin rash or headache has been noted.

Important Drug interactions

Anti-inflammatory drugs (NSAIDs) — additive anti-inflammatory effect; may allow dose adjustment under guidance.
Immunosuppressants — boswellia modulates immune signaling; use cautiously.
Anticoagulants — theoretical additive effect; monitor if combined.

More Joint Health Ingredients

Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Bone Health
Copper
Copper is an essential trace mineral and cofactor for over 30 enzymatic reactions, includi…
Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…
Anti-Inflammatory
Meriva® (Curcumin Phytosome — Indena)
Meriva® is a CURCUMIN PHYTOSOME® formulation developed by Indena (Italy) — using Indena's…

Frequently asked questions about 5-Loxin® (Boswellia AKBA — PLT/OmniActive)

What is 5-Loxin® (Boswellia AKBA — PLT/OmniActive)?

5-Loxin® is a branded Boswellia serrata gum resin extract standardized to a high level (at least 30%) of AKBA (3-O-acetyl-11-keto-beta-boswellic acid), the single most potent anti-inflammatory boswellic acid.

What is the recommended dosage of 5-Loxin® (Boswellia AKBA — PLT/OmniActive)?

The clinically studied dose for 5-Loxin® (Boswellia AKBA — PLT/OmniActive) is 100 to 250 mg once daily. Knee osteoarthritis trials used 100 mg/day and 250 mg/day over 90 days, with benefits seen as early as 7 days at the higher dose.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is 5-Loxin® (Boswellia AKBA — PLT/OmniActive) used for?

5-Loxin® (Boswellia AKBA — PLT/OmniActive) is studied for knee osteoarthritis and joint comfort, joint mobility and stiffness, cartilage-protective signaling. In double-blind, placebo-controlled trials, 5-Loxin significantly reduced pain and improved physical function scores in people with knee osteoarthritis, with the 250 mg dose showing improvement within a week.

Are there side effects from taking 5-Loxin® (Boswellia AKBA — PLT/OmniActive)?

Reported potential side effects may include: GENERALLY WELL-TOLERATED — adverse events in trials were comparable to placebo. Mild digestive upset, such as nausea or acid reflux, is occasionally reported. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Is 5-Loxin® (Boswellia AKBA — PLT/OmniActive) safe to take?

Whether 5-Loxin® (Boswellia AKBA — PLT/OmniActive) is safe depends on the dose, your overall health, and any medications you take. At studied doses, reported side effects can include: GENERALLY WELL-TOLERATED — adverse events in trials were comparable to placebo. It may also interact with certain medications. 5-Loxin® (Boswellia AKBA — PLT/OmniActive) is not suitable for everyone — consult a healthcare provider before use if you are pregnant or breastfeeding, have a medical condition, or take prescription medications.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Sengupta K, Alluri KV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008;10(4):R85..PubMedUsed to support: Pivotal RCT showing pain and function benefit in knee osteoarthritis.
  2. Sengupta K, Krishnaraju AV, Vishal AA, et al. Comparative efficacy and tolerability of 5-Loxin and Aflapin against osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci. 2010;7(6):366-77..PubMedUsed to support: RCT confirming osteoarthritis benefit of AKBA-standardized boswellia.
  3. Vishal AA, Mishra A, Raychaudhuri SP. A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee. Int J Med Sci. 2011;8(7):615-22..PubMedUsed to support: RCT of AKBA-enriched boswellia in knee osteoarthritis.